Novartis is a large pharmaceutical company headquartered in Switzerland that was formed in 1996 through the merger of Ciba-Geigy and Sandoz. Over the years, Novartis has expanded through acquisitions of companies like Alcon, Hexal, and Fougera to become a leader in pharmaceuticals, eye care, generics, and vaccines. The document provides details on Novartis' products, history, acquisitions, organizational structure, marketing issues, financial performance, and strategy for further growth.
Novartis is a large pharmaceutical company based in Switzerland that focuses on developing and marketing new healthcare products. It has three key business segments: Pharmaceuticals, Alcon, and Sandoz. Novartis invests heavily in research and development, spending over $8 billion annually to discover new drugs and improve existing treatments. The company's top-selling pharmaceutical products contribute over 58% of total pharmaceutical revenues.
Novartis is a large Swiss pharmaceutical company formed in 1996 through the merger of Ciba-Geigy and Sandoz. It has over 150,000 employees worldwide and focuses on innovative treatments for diseases like cancer, arthritis, and infectious diseases. The company aims to improve human health and reports annual financial results and other company information in detailed annual reports.
The document provides an overview of Novartis including:
- Its mission is to discover, develop, and market innovative products to prevent and cure diseases while providing returns for shareholders.
- Key facts about its history, people, top brands, product mix, presence in different countries, and financial data including $56.6 billion in total sales in 2012.
- It invests heavily in R&D with locations around the world focusing on areas like rare/neglected diseases and responsible research practices.
With the quantity of pharmaceutical industry expanding each day,competition inside the business is wild.Novartis is pharmaceutical industry.. This year, Novartis experienced success with oncology, immunology and dermatology, eye care and biosimilars.
Competitive advantage and strategy formulation processvitusmaren
This document discusses the competitive advantages and strategy formulation processes of three large pharmaceutical companies: Novartis, Pfizer, and Sanofi-Aventis. It outlines how Novartis was formed through a merger and leads in various therapeutic areas. Pfizer invests heavily in research and develops blockbuster drugs. Sanofi-Aventis has a large diversified drug portfolio and global vaccine leadership. The strategy formulation process for Novartis is also summarized, including its mission to discover and market innovative products, objectives like eliminating diseases, and potential strategies like investing in R&D.
Novartis is a global healthcare company headquartered in Switzerland that employs over 115,000 people worldwide. It was created in 1996 through the merger of Ciba-Geigy and Sandoz. Novartis operates in India through four entities and has a presence in pharmaceuticals, generics, vaccines, consumer health, eye care, and animal health. Some of Novartis' most visible and successful products include the diabetes drug Galvus, the hypertension drug Diovan, and the anticonvulsant Tegretol.
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine.
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
Novartis is a large pharmaceutical company based in Switzerland that focuses on developing and marketing new healthcare products. It has three key business segments: Pharmaceuticals, Alcon, and Sandoz. Novartis invests heavily in research and development, spending over $8 billion annually to discover new drugs and improve existing treatments. The company's top-selling pharmaceutical products contribute over 58% of total pharmaceutical revenues.
Novartis is a large Swiss pharmaceutical company formed in 1996 through the merger of Ciba-Geigy and Sandoz. It has over 150,000 employees worldwide and focuses on innovative treatments for diseases like cancer, arthritis, and infectious diseases. The company aims to improve human health and reports annual financial results and other company information in detailed annual reports.
The document provides an overview of Novartis including:
- Its mission is to discover, develop, and market innovative products to prevent and cure diseases while providing returns for shareholders.
- Key facts about its history, people, top brands, product mix, presence in different countries, and financial data including $56.6 billion in total sales in 2012.
- It invests heavily in R&D with locations around the world focusing on areas like rare/neglected diseases and responsible research practices.
With the quantity of pharmaceutical industry expanding each day,competition inside the business is wild.Novartis is pharmaceutical industry.. This year, Novartis experienced success with oncology, immunology and dermatology, eye care and biosimilars.
Competitive advantage and strategy formulation processvitusmaren
This document discusses the competitive advantages and strategy formulation processes of three large pharmaceutical companies: Novartis, Pfizer, and Sanofi-Aventis. It outlines how Novartis was formed through a merger and leads in various therapeutic areas. Pfizer invests heavily in research and develops blockbuster drugs. Sanofi-Aventis has a large diversified drug portfolio and global vaccine leadership. The strategy formulation process for Novartis is also summarized, including its mission to discover and market innovative products, objectives like eliminating diseases, and potential strategies like investing in R&D.
Novartis is a global healthcare company headquartered in Switzerland that employs over 115,000 people worldwide. It was created in 1996 through the merger of Ciba-Geigy and Sandoz. Novartis operates in India through four entities and has a presence in pharmaceuticals, generics, vaccines, consumer health, eye care, and animal health. Some of Novartis' most visible and successful products include the diabetes drug Galvus, the hypertension drug Diovan, and the anticonvulsant Tegretol.
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine.
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
Sanofi reported its Q4 and full year 2021 results. The document contains forward-looking statements and discusses Sanofi's Q4 performance, pipeline progress, and planned upcoming launches. Key highlights include Specialty Care becoming Sanofi's largest business unit driven by strong Dupixent sales of €1.5 billion in Q4. The pipeline was also strengthened with the addition of 36 projects in phase I/II.
This document outlines Sanofi's strategic roadmap for 2015-2020. It discusses Sanofi's vision of being a focused global healthcare company in pharmaceuticals, vaccines, and consumer healthcare. The roadmap identifies four strategic priorities: 1) reshaping the portfolio, 2) delivering outstanding launches, 3) simplifying the organization, and 4) sustaining innovation in R&D. Specific goals and initiatives are outlined for each of Sanofi's global business units.
DRA (Drug Regulatory Affairs) , RA (Regulatory Affairs)Naman Ruhela
A Brief Introduction about the Regulatory Affairs / Drug Regulatory Affairs (DRA). Introduction to Drug Regulatory Affairs. Why Drug Regulatory Affairs?. Role of Regulatory Affairs Experts. Types of the company hiring RA professionals. RA professional can get employment. Regulatory Bodies.
The pharmaceutical industry in India is sized at $5 billion currently ranked 4th in terms of volume and 13th in terms of value, growing at an annual rate of 14.3% and expected to reach $25 billion by 2010. There are over 23,000 pharma companies in India but only around 300 operate in the organized sector. Novartis India is a 51% subsidiary of Swiss company Novartis, established in India in 1996. Novartis India's pharmaceuticals business contributes 62% of its sales and it has grown its total income over the years from 2004-2007 but profitability has been impacted by price regulations in India.
The clinical trial process is one of the most critical and necessary steps for the development of all new drugs,
biologics or medical devices. Conducting clinical trials in Japan requires a delicate balancing act between having a
thorough understanding of the Japanese regulatory framework, as well as having an even much better
understanding of how clinical trials must be managed within the nuances and boundaries of the Japanese culture.
Sun Pharmaceutical Industries is an Indian pharmaceutical company headquartered in Mumbai. It manufactures generic and branded formulations as well as active pharmaceutical ingredients. The company offers a range of products across several therapeutic areas. It became the fifth largest generic company in the world after acquiring Ranbaxy Laboratories in 2014. An analysis of Sun Pharma's financial ratios from 2011-2015 showed that the company generally maintained healthy profitability and liquidity ratios during this period, though some ratios like interest coverage declined over time, potentially due to increased borrowing.
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
The document discusses regulatory requirements for drug registration in Asian countries. It provides an overview of the ASEAN Common Technical Dossier (ACTD) format for drug applications across ASEAN countries. It then summarizes requirements for registration in China, South Korea, and with the ASEAN region. For China, it outlines the drug classification system and two-step approval process. For South Korea, it describes the drug classification and approval process including investigational new drug applications. It also provides background on the goals and formation of the ASEAN economic alliance between Southeast Asian countries.
Pharmaceutical Industry Global & Indianprateek_floyd
The document discusses the global pharmaceutical industry. It provides data showing steady growth in global pharmaceutical sales from 2003-2012, with the US market accounting for the largest share. The top 10 pharmaceutical companies are also listed. R&D spending and trends in major markets like the US, Europe, and Japan are examined. Details are also provided about the large and growing pharmaceutical industries in India and their competitive advantages in generics manufacturing.
Sun Pharmaceutical Industries is an Indian pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and the United States. Started in 1983 with five psychiatry products, it is now India's largest chronic prescription drug company and a market leader in several therapeutic areas. In 2015, its acquisition of Ranbaxy made it the largest pharmaceutical company in India. The presentation concludes that Sun Pharmaceuticals is performing well financially, has significant potential for growth, and as the world's 5th largest pharmaceutical company after acquiring Ranbaxy, it is recommended for investment.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
Financial analysis of novartis pharmaceuticalsyashicaj9
Novartis Pharmaceuticals is an international healthcare company headquartered in Switzerland. The document analyzes Novartis' financial performance in India from 2012-2011 through ratio analysis. Key findings include:
1. Liquidity ratios like current and quick ratios show Novartis had a more satisfactory short-term financial position in 2011 compared to 2012.
2. Leverage and proprietary ratios measuring long-term solvency were satisfactory for both years.
3. Turnover ratios for inventory, fixed assets, and working capital were generally higher in 2011, indicating more efficient utilization of company resources that year compared to 2012.
4. Overall, the ratio analysis found Novartis' financial management
Regulatory affairs is a profession that has developed to ensure the safety and efficacy of regulated products like pharmaceuticals, medical devices, and cosmetics. Regulatory affairs professionals are responsible for understanding and complying with regulations, collecting scientific data, and submitting applications to regulatory agencies to obtain approval to market products. They provide strategic guidance to companies on navigating the regulatory process from product development through marketing approval and post-market compliance. Ensuring compliance with regulations governing manufacturing, quality management systems, advertising, and other areas is important for regulatory affairs.
This document provides an overview of the pharmaceutical industry in India. It discusses the history and growth of the Indian pharmaceutical market. It also describes the various types of companies, customers, marketing approaches, distribution channels, roles of sales, marketing, and other teams, pricing regulations, and opportunities and changes in the industry. The document is an extensive guide covering many aspects of the pharmaceutical business in India.
Johnson & Johnson Pharmaceutical Business ReviewDeepa K
The document is an agenda for an investor presentation. It outlines the schedule for the day which includes presentations on the company's enterprise overview, pharmaceutical commercial and R&D strategies, and various therapeutic areas. It also includes notices about forward-looking statements and new molecular entities being discussed. The speakers and locations are listed next to each topic.
Mergers and Acquisitions in Indian Pharma IndustryNaveen Kumar
The document discusses mergers and acquisitions (M&A) in the Indian pharmaceutical industry. It provides reasons for the increasing M&A activity, such as patent cliffs, expanding markets, high R&D costs, and the need to increase market share. It outlines some of the major M&A deals involving Indian pharmaceutical companies, including Abbott's acquisition of Piramal for $3.72 billion, one of the largest pharma deals in India. The future of M&A activity in the industry is also discussed.
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
Ranveer Sharma from the Department of Biotech at Bcet Gurdaspur presented on Panacea Biotec. Panacea Biotec is an Indian healthcare company focused on pharmaceuticals, biopharmaceuticals, vaccines and natural products. It has a global footprint in over 30 countries. Key highlights included its #4 ranking in vaccines in India, state-of-the-art manufacturing facilities approved by US FDA and WHO, and strategic collaborations with companies like Serum Institute of India and Apotex. Recent updates discussed a collaboration with Serum Institute on a hexavalent vaccine and a settlement agreement with Celgene regarding patents on Panacea's generic version of Abraxane.
Novartis has been operating in India since 1947 through various entities. It has a presence in pharmaceuticals, generics, vaccines, over-the-counter medicines, and eye care. Novartis' mission is to discover, develop, and market innovative products to prevent and cure diseases while enhancing quality of life. Its vision is to provide shareholder returns through outstanding performance. Novartis invests heavily in research and development through its institute and sees R&D as key to innovation and meeting unmet medical needs.
Sanofi reported its Q4 and full year 2021 results. The document contains forward-looking statements and discusses Sanofi's Q4 performance, pipeline progress, and planned upcoming launches. Key highlights include Specialty Care becoming Sanofi's largest business unit driven by strong Dupixent sales of €1.5 billion in Q4. The pipeline was also strengthened with the addition of 36 projects in phase I/II.
This document outlines Sanofi's strategic roadmap for 2015-2020. It discusses Sanofi's vision of being a focused global healthcare company in pharmaceuticals, vaccines, and consumer healthcare. The roadmap identifies four strategic priorities: 1) reshaping the portfolio, 2) delivering outstanding launches, 3) simplifying the organization, and 4) sustaining innovation in R&D. Specific goals and initiatives are outlined for each of Sanofi's global business units.
DRA (Drug Regulatory Affairs) , RA (Regulatory Affairs)Naman Ruhela
A Brief Introduction about the Regulatory Affairs / Drug Regulatory Affairs (DRA). Introduction to Drug Regulatory Affairs. Why Drug Regulatory Affairs?. Role of Regulatory Affairs Experts. Types of the company hiring RA professionals. RA professional can get employment. Regulatory Bodies.
The pharmaceutical industry in India is sized at $5 billion currently ranked 4th in terms of volume and 13th in terms of value, growing at an annual rate of 14.3% and expected to reach $25 billion by 2010. There are over 23,000 pharma companies in India but only around 300 operate in the organized sector. Novartis India is a 51% subsidiary of Swiss company Novartis, established in India in 1996. Novartis India's pharmaceuticals business contributes 62% of its sales and it has grown its total income over the years from 2004-2007 but profitability has been impacted by price regulations in India.
The clinical trial process is one of the most critical and necessary steps for the development of all new drugs,
biologics or medical devices. Conducting clinical trials in Japan requires a delicate balancing act between having a
thorough understanding of the Japanese regulatory framework, as well as having an even much better
understanding of how clinical trials must be managed within the nuances and boundaries of the Japanese culture.
Sun Pharmaceutical Industries is an Indian pharmaceutical company headquartered in Mumbai. It manufactures generic and branded formulations as well as active pharmaceutical ingredients. The company offers a range of products across several therapeutic areas. It became the fifth largest generic company in the world after acquiring Ranbaxy Laboratories in 2014. An analysis of Sun Pharma's financial ratios from 2011-2015 showed that the company generally maintained healthy profitability and liquidity ratios during this period, though some ratios like interest coverage declined over time, potentially due to increased borrowing.
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
The document discusses regulatory requirements for drug registration in Asian countries. It provides an overview of the ASEAN Common Technical Dossier (ACTD) format for drug applications across ASEAN countries. It then summarizes requirements for registration in China, South Korea, and with the ASEAN region. For China, it outlines the drug classification system and two-step approval process. For South Korea, it describes the drug classification and approval process including investigational new drug applications. It also provides background on the goals and formation of the ASEAN economic alliance between Southeast Asian countries.
Pharmaceutical Industry Global & Indianprateek_floyd
The document discusses the global pharmaceutical industry. It provides data showing steady growth in global pharmaceutical sales from 2003-2012, with the US market accounting for the largest share. The top 10 pharmaceutical companies are also listed. R&D spending and trends in major markets like the US, Europe, and Japan are examined. Details are also provided about the large and growing pharmaceutical industries in India and their competitive advantages in generics manufacturing.
Sun Pharmaceutical Industries is an Indian pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients primarily in India and the United States. Started in 1983 with five psychiatry products, it is now India's largest chronic prescription drug company and a market leader in several therapeutic areas. In 2015, its acquisition of Ranbaxy made it the largest pharmaceutical company in India. The presentation concludes that Sun Pharmaceuticals is performing well financially, has significant potential for growth, and as the world's 5th largest pharmaceutical company after acquiring Ranbaxy, it is recommended for investment.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
Financial analysis of novartis pharmaceuticalsyashicaj9
Novartis Pharmaceuticals is an international healthcare company headquartered in Switzerland. The document analyzes Novartis' financial performance in India from 2012-2011 through ratio analysis. Key findings include:
1. Liquidity ratios like current and quick ratios show Novartis had a more satisfactory short-term financial position in 2011 compared to 2012.
2. Leverage and proprietary ratios measuring long-term solvency were satisfactory for both years.
3. Turnover ratios for inventory, fixed assets, and working capital were generally higher in 2011, indicating more efficient utilization of company resources that year compared to 2012.
4. Overall, the ratio analysis found Novartis' financial management
Regulatory affairs is a profession that has developed to ensure the safety and efficacy of regulated products like pharmaceuticals, medical devices, and cosmetics. Regulatory affairs professionals are responsible for understanding and complying with regulations, collecting scientific data, and submitting applications to regulatory agencies to obtain approval to market products. They provide strategic guidance to companies on navigating the regulatory process from product development through marketing approval and post-market compliance. Ensuring compliance with regulations governing manufacturing, quality management systems, advertising, and other areas is important for regulatory affairs.
This document provides an overview of the pharmaceutical industry in India. It discusses the history and growth of the Indian pharmaceutical market. It also describes the various types of companies, customers, marketing approaches, distribution channels, roles of sales, marketing, and other teams, pricing regulations, and opportunities and changes in the industry. The document is an extensive guide covering many aspects of the pharmaceutical business in India.
Johnson & Johnson Pharmaceutical Business ReviewDeepa K
The document is an agenda for an investor presentation. It outlines the schedule for the day which includes presentations on the company's enterprise overview, pharmaceutical commercial and R&D strategies, and various therapeutic areas. It also includes notices about forward-looking statements and new molecular entities being discussed. The speakers and locations are listed next to each topic.
Mergers and Acquisitions in Indian Pharma IndustryNaveen Kumar
The document discusses mergers and acquisitions (M&A) in the Indian pharmaceutical industry. It provides reasons for the increasing M&A activity, such as patent cliffs, expanding markets, high R&D costs, and the need to increase market share. It outlines some of the major M&A deals involving Indian pharmaceutical companies, including Abbott's acquisition of Piramal for $3.72 billion, one of the largest pharma deals in India. The future of M&A activity in the industry is also discussed.
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
Ranveer Sharma from the Department of Biotech at Bcet Gurdaspur presented on Panacea Biotec. Panacea Biotec is an Indian healthcare company focused on pharmaceuticals, biopharmaceuticals, vaccines and natural products. It has a global footprint in over 30 countries. Key highlights included its #4 ranking in vaccines in India, state-of-the-art manufacturing facilities approved by US FDA and WHO, and strategic collaborations with companies like Serum Institute of India and Apotex. Recent updates discussed a collaboration with Serum Institute on a hexavalent vaccine and a settlement agreement with Celgene regarding patents on Panacea's generic version of Abraxane.
Novartis has been operating in India since 1947 through various entities. It has a presence in pharmaceuticals, generics, vaccines, over-the-counter medicines, and eye care. Novartis' mission is to discover, develop, and market innovative products to prevent and cure diseases while enhancing quality of life. Its vision is to provide shareholder returns through outstanding performance. Novartis invests heavily in research and development through its institute and sees R&D as key to innovation and meeting unmet medical needs.
Fact sheet presenting the life sciences industry in the Quebec City region. Produced by Quebec International. http://quebecinternational.ca/key-industries/
Baxter International's 1996 annual report outlines its vision to be recognized as a leader in innovative healthcare technologies that improve lives. It has leading market positions in four businesses: biotechnology, cardiovascular medicine, renal therapy, and intravenous systems/medical products. All of Baxter's businesses hold leading positions in high-growth global markets and are pursuing the vision through talented and dedicated people.
The 10 most trusted vaccine solution providers, 2020Merry D'souza
In this edition, ‘The 10 Most Trusted Vaccine Solution Providers, 2020’ CIO Look has shortlisted various healthcare organizations which are playing an important role towards the global healthcare system.
This document discusses biotechnology and its role in addressing the COVID-19 pandemic. It outlines the main branches of biotechnology including blue, green, bioinformatics, red, and white biotechnology. It also lists top biotech companies in India and specializations within biotechnology. The document explains opportunities for biotech companies to develop vaccines, drugs, and medical equipment for COVID-19. Governments are supporting biotech industry efforts to rapidly develop treatments and remedies for the pandemic.
Vaxeal is a biopharmaceutical company developing therapeutic cancer vaccines and treatments for infectious diseases. It has several vaccine candidates in pre-clinical development targeting cancers and hepatitis C that are expected to begin clinical trials in Europe in 2014-2015. Vaxeal takes promising early-stage research from academic partners and advances it through clinical proof-of-concept, with the goal of improving patient access to new treatments.
Roche and Genentech are leading healthcare companies dedicated to innovation in a sustainable way. Roche was founded in 1896 in Basel and still has majority family ownership. It has over 100,000 employees worldwide and sales of 62.8 billion CHF in 2021. Roche invests heavily in R&D and healthcare and was among the top companies in the Dow Jones Sustainability Index for 13 consecutive years. Genentech was the first publicly-owned biotech company. Roche has a unique innovation model with independent research centers worldwide and global product development, manufacturing, and commercialization. It manages over 250 partnerships and is optimally positioned as the leader in personalized healthcare through diagnostics, therapies, and decision support. Roche Partnering has
Wolff Medical Marketing & Design is a company that designs and manufactures promotional products for the pharmaceutical industry. Founded in the 1980s, it has worked with major drug brands. After being acquired, the founder started Wolff Medical in 1997 to continue in the industry. It provides creative, innovative products to help pharmaceutical clients strengthen their brands and relationships with physicians and patients.
Neuroscience is poised for increased deal activity after a period of setbacks. Advances in clinical trial design, imaging, and biomarkers are driving interest in neuroscience drugs. Venture funding and licensing deals in neurology and psychiatry totaled billions from 2005-2014, though M&A activity was lower. Recent large neuroscience acquisitions by companies like Celgene, Teva, and Biogen have sparked renewed enthusiasm. Experts predict precision medicine approaches will increase dealmaking as neurological diseases are further subtyped genetically.
This document provides an overview of Venus Glucose Pvt. Ltd., an Indian pharmaceutical company. It discusses the company's history since 1989, key milestones and expansions. The company has manufacturing facilities in India and Germany, and focuses on research and development, generics, and key therapeutic areas like analgesics, antibiotics and anti-diabetics. The document also outlines the company's vision, mission and focus on developing drugs for antimicrobial resistance. It introduces the executive team and provides an organizational structure.
NECC produced tainted drug that killed over 40 people and sickened over 700. This presentation explores the quality and microbiology failures that lead to this catastrophe.
1- MarketingBefore putting the product into the market, the prod.docxmonicafrancis71118
1- Marketing
Before putting the product into the market, the product goes through several stages. One of the most important stages is to determine the price of the product. After that, it will be studied by asking questions to customers and anticipate their requirements in terms of shape, colour phrases recorded on it. It can be applied using servery or interview the customer. Finally, the product needs to be promoting before it is been released, so electronic, and visual and audio can be used as advertising. However, in this experiment, we will focus only on the total cost of the product and then work on finding who develops the product….[9] [10].
1.1 Estimating of the total price.
For the antibiotic spray, it can be estimate the total price depend on the type of the material which were be used. Thus, the material in the table estimates the total price.
Material
Discerption
Brand/ manufacture
Price Ink VAT.
[1] Cefuroxime(as Cefuroxime sodium) 1.5 gram.
CEFUROXIME is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections
£4.70
[2] Sterile Water (1000ml)
Single Bottle of Sterile Water (1000ml)
Baxter
£3.54
[3] 73.5 mg of sodium
Sodium Bicarbonate 2kg - Pharmaceutical Grade (Bicarb/Bicarbonate of Soda)
£6.49
[1] Metronidazole
Metronidazole 500mg/100ml infusion 100ml bags (A A H Pharmaceuticals Ltd)
£63.86
[4] Phosphatebuffer (pKa=7.2)
PBS405.1 Virtual PHOSPHATE BUFFERED SALINE pH 7.4 10X Liquid Concentrate, 1L
£22.75
[5] Brilliant Blue FCF
1 kilogram
£6-8
[6] 100ml Stainless Steel
Empty stainless bottle spray
£7-9
Total price
£118
2- Companies and industry
There are many companies interested to work on or collaborate for developing the antibiotic. Following, there are some of the companies, Charities and universities, which they work hardly to improve public health and more specifically in the development of antibiotics. Thus, the product will be a focuses for them and new idea that can be started to develop and prove its effectiveness. Then, it can be put in the market, which many people can take advantage of the ease and licences of the product.
2.1. GSK Company [13]
At GSK, they are at the forefront of researching new ways to tackle some of the world’s biggest healthcare challenges. So as antibiotic resistance grows, they are investing in new ways to fight infection.
Their approach is to make the most of their own expertise and experience, while at the same time forming complementary partnerships and alliances with others who bring different kinds of expertise. Their vision for the world, where everyone has access to the vaccines they need, depends on a steady supply of great ideas and brilliant science. They have much to offer and through collaboration, they can achieve so much more.
For example, more than 90% of the vaccines in their pipeline are being developed in partnership with others. They have a long track rec.
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
Stablepharma Overview September 2016 Linkedin versionBruce Roser
Stablepharma has developed a patented process to stabilize vaccines by drying them with trehalose sugar in a sponge inside a syringe. This allows vaccines to be stored without refrigeration for long periods of time. Initial animal testing of their stabilized tetanus vaccine showed full effectiveness after storage at high temperatures, validating the technology. Stablepharma aims to license their technology to large vaccine manufacturers or produce their own stabilized vaccines to sell to organizations like WHO and UNICEF to help address the estimated 50% of vaccines that are wasted globally due to unreliable refrigeration. Their stabilized vaccines have the potential to save millions of lives and hundreds of millions of dollars annually.
Nestlé is expanding into the healthcare field through its new division, Nestlé Health Science. The presentation discusses opportunities in healthcare given trends of aging populations and increasing chronic diseases. It introduces Nestlé Health Science's vision to provide personalized nutrition solutions for medical conditions. Currently, Nestlé has a healthcare nutrition business and is expanding its scientific platforms and diagnostic capabilities through acquisitions to build a transformational healthcare business over the next 5 years.
This issue of Pharma Uptoday provides news and updates in the pharmaceutical industry. Key items include:
1) Fareva buys a Merck API plant in France and plans to invest €25 million to upgrade it for handling highly potent compounds.
2) Strides completes its acquisition of Aspen's generic business in Australia for Rs 1,910 crore.
3) Aurobindo Pharma receives USFDA approval for its generic version of the hepatitis B drug Entecavir.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
2. 2
Table of Contents
Contents
AboutNovartis...............................................................................................................................................3
COMPANY PRODUCTS:....................................................................................................................................3
HISTORY OF NOVARTIS....................................................................................................................................3
Pattern of actions by Novartis .........................................................................................................................7
New product development growth strategy.....................................................................................................8
Strategy Changes due to external environment................................................................................................9
ACQUISITION HISTORY OF NOVARTIS.............................................................................................................10
Novartis Organizational Structure..................................................................................................................13
A brief of all the structures and its roles in the organization............................................................................14
MAJOR ISSUES IN MARKETING SECTOR OF NOVARTIS.....................................................................................16
NOVARTIS-OFF-LABEL MARKETING AND OTHER MARKETING VIOLATIONS: ..................................................16
NOVARTIS DEALS GROUP INCLUDED IN FIXING STOCKISTS FORA YEAR:.......................................................17
UNITED STATES CLAIMBLAMES NOVARTIS FOR HEALTH AWARENESS MISREPRESENTATION ........................18
FINANCIAL ANALYSIS.....................................................................................................................................19
NET INCOME ............................................................................................................................................21
DRIVER TO RISE IN NET INCOME (2010 onward) .........................................................................................22
TOTAL ASSETS...........................................................................................................................................23
SHARE PRICE.............................................................................................................................................24
CONCLUSION, RECOMMENDATIONS, FUTURE PROSPECTS..............................................................................25
Pipeline....................................................................................................................................................25
References...................................................................................................................................................26
3. 3
About Novartis
Novartis is the only healthcare company with leading positions in pharmaceuticals, eye care, generic
medicines, vaccines and diagnostics, as well as consumer and animal health products. Our medicines
reach more than 1 billion people around the world every year.
Novartis is headquartered in Basel, Switzerland. Novartis Group companies employ approximately
130000 associates who are citizens of more than 150 nations. We operate in more than 140 countries
around the world.
COMPANY PRODUCTS:
The company's Pharmaceuticals Division focuses on researching, developing and manufacturing
treatments across a variety of therapeutic areas, including: auto-immunity, cardiovascular, dermatology,
infectious diseases, metabolism, neuroscience, oncology, ophthalmology, respiratory, rheumatology, and
transplantation.
HISTORY OF NOVARTIS
1996
Sygenta is created through the merger of the agriculture business units of Novartis and Astra Zeneca.
Anti-viral products Farnvir and Vectavir are acquired from GSK Beecham.
Novartis American Depositary Shares are listed in NYSE.
Establishment of Novartis Institute of Functional Genomics.
Novartis is created through the merger of Ciba-Geigy and Sandoz to create one of the world’s largest
healthcare companies.
2002
Novartis increases investment in Roche Holding AG to 1/3rd voting shares.
LEK Pharma is acquired for 900 Mn
Novartis divested the Health and functional Food Business.
4. 4
Novartis unifies and strengthens its global research by creating the Novartis Institutes for
Biomedical research.
2003
Adult Business nutrition business of MEAD Johnson and company is announced.
A majority interest in Idenix Pharma Inc. a US based Biotech Company focused on antiviral and
anti-infective therapies is acquired as part of a strategic expansion into antiviral medicines.
2004
Novartis institute for Tropical Diseases opens in Singapore with a focus on biomedical research
for dengue fever and drug resistant tuberculosis.
Novartis acquires two generics companies: the Danish firm Durasacan A/S from AstraZeneca
and Sabex Holdings Ltd of Canada.
Novartis submits Xolair for EU approval for the treatment of Allergic asthma.
The NIBR announce a joint project with the broad institute of MIT and Harvard to research the
genetic causes of type 2 diabetes.
Unification of several Novartis generic pharma businesses joining Pharma and consumer health.
Novartis Foundation for sustainable development celebrates 25th anniversary.
2005
Novartis acquires Hexal AG. Leading Generics Company based in Germany and Eon Labs an
American generics co making Sandoz a world leader in generic pharma.
Novartis reaches agreement to buy the remaining stake in Chiron Co and acquiring.
Novartis and Alnylam Pharma create an alliance focused on discovering innovative therapies
based on RNAi.
2006
Novartis announces the creation of a strategic biomedical R&D Centre in Shanghai, China.
The NITD initiates research on malaria as part of a new public private partnership.
Partnership with WHO Novartis for nonprofit distribution of malaria in developing countries.
The US Department of Health and Human services grants Novartis a contract for up to USD 220
million to build a cell culture-based influenza vaccine production plant in the US. Recognizing
Novartis as a leader in influenza vaccine development.
5. 5
Received approval of Omni trope is part of Sandoz strategy to offer follow on biotech products
after patent expiry.
2007
Novartis enhances its vaccine pipeline through partnership with intercell. Intercell develops
vaccines to prevent and treat infectious diseases.
Novartis is solely focused on health care after completing non-core business disinvestments of
the Gerber and Medical Nutrition Business Units to Nestle for USD 5.5 billion and USD 2.5
billion
Novartis is ranked No.1 among Pharma companies in Fortune magazine’s survey.
NITD inaugurates an Indonesian research initiative to study dengue fever, tuberculosis and
malaria.
Tekturna the first new type of high blood pressure medicine in more than a decade.
2008
Novartis reaches agreement with Nestle SA to acquire majority ownership of Alcon Inc. the
world leader in eye care with pharmaceutical, surgical and consumer products.
Novartis opens a new vaccine research Centre institute in Italy. Novartis Vaccines Institute for
Global Health whose focus on the development of vaccines for disease for the developing world.
Novartis is named healthcare super sector leader in 2008 and “World’s most ethical companies”.
No. 20 in the most respected companies in the world.
Gleevec is approved for treatment for use after gastrointestinal stromal tumour surgery.
Novartis announces 20% reduction in the price of its anti-malaria medicine Coartem due to
efficiency gains in production.
2009
Novartis delivers the 250 millionth treatment of Coartem a highly effective artemisinin based
combination therapy for malaria. From 2001 to the end of 2009, a total of 300 million treatments
have been delivered, saving an estimated 750,000 lives in more than 60 malaria-endemic countries.
Novartis was the first company to produce the Influenza a (H1N1) vaccine with modern cell structure
bio technology that complements 50-year old egg based production process.
Novartis announces USD 1 billion investment over five years in China to build the country’s largest
pharma R&D institute.
6. 6
Pervacid24Hr launches in pharma and retail stores across the US to treat frequent heartburn for a full
24hrs with one pill a day. The launch marks one of the biggest Rx to OTC switches in the US.
2010
New management is in place for the next phase of the growth.
Buying out the remaining stake in Alcon and merging it into Novartis. The addition of eye care
will strengthen the Novartis healthcare portfolio and provide greater access to this attractive
sector.
2011
Vaccines and medicines from Novartis reach an estimated 1 billion patients.
Alcon merger completed
Since 2001, 450 million Coartem treatments delivered to patients saving 1 million lives.
New malaria drug with dual acting class of compound.
No.1 in fortune magazine.
2012
Industry’s first water gradient silicone hydrogel contact lens and Flucelvax, the first cell culture
vaccine in the US to help protect against seasonal influenza
Fougera Pharma acquired by Sandoz made it the world’s number one generic dermatology
medicines co in the US and globally.
100 million patients reached through access to health care programs valued at USD 2 billion.
2013
Management change.
Novartis' current product portfolio includes more than 50 key marketed products and in 2012, the
company had 13 new products approved in the United States, Europe and Japan.
7. 7
Pattern of actions by Novartis
Buying out the remaining stake in Alcon and merging it into Novartis. The addition of eye care will
strengthen the Novartis healthcare portfolio and provide greater access to this attractive sector.
Novartis announces 20% reduction in the price of its anti malaria medicine Coartem due to
efficeincy gains in production.
Novartis announces USD 1 billion investment over five years in China to build the country’s largest
pharma R&D institute.
Pervacid24Hr launches in pharma and retail stores across the US to treat frequent heartburn for a
full 24hrs with one pill a day. The launch marks one of the biggest Rx to OTC swtiches in the US
8. 8
Novartis acquires Hexal AG. Leading generics company based in Germany and Eon Labs an
American generics co making Sandoz a world leader in generic pharma.
The NIBR (Novartis Institutes for Biomedical research. Announce a joint project with the broad
institute of MIT and Harvard to research the genetic causes of type 2 diabetes.
New management is in place for the next phase of the growth.
Novartis enhances its vaccine pipeline through partnership with intercell. Intercell develops
vaccines to prevent and treat infectious diseases.
Due to the scattered distribution of buyers throughout the world for Novartis, there isn’t much
bargaining leverage for them. There are numerous suppliers that have registered in the portal of
Novartis which aims to do business with Novartis. Therefore, it is not easy for the supplier to drive
up their prices.
New product development growthstrategy
Status Quo Product
Development
Market Penetration Market
Development
Existing New
Existing
New
CUSTOMERS
PRODUCTS
9. 9
Strategy Changes due to external environment
Novartis has increased its portfolio with both innovations and acquisitions while focusing on specific
market segments by divesting businesses. It has a strategic focus in eye care, prescription, and generic
pharmaceutical products and has a portfolio of biosimilars in development through its Sandoz business
unit.
In 2013, Novartis announced that it would be closing its La Jolla, California biotherapeutics
development unit, signaling a departure from developing new topical dermatology products. Sandoz, the
generics business of Novartis, announced the acquisition of Fougera Pharmaceuticals in 2012. This
acquisition advanced the portfolio and geographic presence of the Novartis generic dermatology
medicines segment.
The company also announced a licensing and research agreement with Regenerex LLC. Part of the
agreement concerns the novel Facilitating Cell Therapy (FCRx) platform from Regenerex, which is
being used for transplantation product development.
In 2012, Novartis and the University of Pennsylvania entered an agreement regarding the development
of chimeric antigen receptor (CAR) technology for cancer treatment. Novartis licensed worldwide rights
to the lead project, CART-19.
Cancer research companies always get funding from government and WHO and most of the money is
spent in R&D. As a large pharma company it is important to
In 2011, Novartis completed several more acquisitions including:
Zhejiang Tianyuan vaccines company (China); and
Genoptix a leader in diagnostics.
Sales of prescription drugs in China will grow by US$40 billion through 2013 and the entry into the Chinese
market was a great step in helping them improve sales figures.
In August 2010, Novartis completed the full acquisition of Alcon, a leading ophthalmic pharmaceuticals
and device company. Alcon had major corporate centers in Switzerland and Texas. In 2007, Novartis
sold its nutrition businesses, including Gerber and the Medical Nutrition unit, to Nestlé S.A.
10. 10
Novartis: 1996 – today
The first CEO of Novartis was Dr Daniel Vasella. Vasella was hired by Sandoz back in 1988 and
remained there until 1992 when he was promoted to CEO of its parent company, Sandoz Pharma.
Vasella helped to orchestrate the merger between Sandoz and Ciba-Geigy and was appointed CEO of
the combined entity. He was also on the Board of Directors and was named Chairman in 1999. Vasella
stepped down as Novartis' CEO in January 2010 and was replaced by Joseph Jimenez, who was the
Division Head of Novartis Pharmaceuticals. He also recently announced his retirement as Chairman of
the Board of Directors and was succeeded by Jorg Reinhard in August 2013.
Since its establishment, Novartis has unified and strengthened its global business and research network:
ACQUISITION HISTORY OF NOVARTIS
1996
Sygenta is created through the merger of the agriculture business units of Novartis and Astra
Zeneca.
Anti-viral products Farnvir and Vectavir are acquired from GSK Beecham.
Novartis is created through the merger of Ciba-Geigy and Sandoz to create one of the world’s
largest healthcare companies.
2002
Novartis increases investment in Roche Holding AG to 1/3rd voting shares.
LEK Pharma is acquired for 900 Mn in Slovenia to help expand its operations there.
2003
A majority interest in Idenix Pharma Inc. a US based Biotech Company focused on antiviral and
anti-infective therapies is acquired as part of a strategic expansion into antiviral medicines.
11. 11
2004
Novartis acquires two generics companies: the Danish firm Durasacan A/S from AstraZeneca
and Sabex Holdings Ltd of Canada.
2005
Novartis acquires Hexal AG. Leading Generics Company based in Germany and Eon Labs an
American generics co making Sandoz a world leader in generic pharma.
Novartis reaches agreement to buy the remaining stake in Chiron Co, USA and acquiring it to
become its subsidiary.
2007
Novartis enhances its vaccine pipeline through partnership with intercell. Intercell develops
vaccines to prevent and treat infectious diseases.
2008
Novartis reaches agreement with Nestle SA to acquire majority ownership of Alcon Inc. the
world leader in eye care with pharmaceutical, surgical and consumer products.
2010
New management is in place for the next phase of the growth.
Buying out the remaining stake in Alcon and merging it into Novartis. The addition of eye care
will strengthen the Novartis healthcare portfolio and provide greater access to this attractive
sector.
2011
Alcon merger completed
2012
Fougera Pharma acquired by Sandoz made it the world’s number one generic dermatology
medicines co in the US and globally.
100 million patients reached through access to health care programs valued at USD 2 billion.
2013
Management change.
12. 12
"Today, in 2013, over 125,000 people work for Novartis – 47% in Europe, 24% in Africa, Asia and
Australia, 21% in the USA and 8% in Canada and Latin America."
The main portion of employees (over 60,000) work in pharmaceuticals – the company's main focus –
while the rest are split between Alcon, Sandoz, Vaccines and Diagnostics, Consumer Health, Shared
services and Corporate.
The main strategy used by Novartis has been Mergers and Acquisitions. The company has slowly built
its presence in countries where it has seen a long-term growth prospects.
Green field strategy ahs been used in Asia to help counter fake medicines and misappropriation of drugs
being exported to these countries.
Brownfield Acquisitions have been the norm in the rest of the world including Europe and USA where
there is availability of technology and easy knowledge sharing is possible.
The history of Novartis clearly identifies this company heading towards massive internationalization to
help grow its company in order for it to become the world’s biggest pharmaceutical company.
Novartis' mission is to: "discover, develop and successfully market innovative products to prevent and
cure diseases, to ease suffering and to enhance the quality of life".
13. 13
Novartis Organizational Structure
The above picture is the current organizational structure of Novartis and has remained similar ever since
its inception in 1996. New acquired companies such as Alcon were placed appropriately.
NIBR
Dr. Mark Fishman
Alcon
Jeff George
Novartis Organizational Structure
Chairman
Board of Directors
Dr. Jörg Reinhardt
Internal Audit
Peter Elam
CEO
Joseph Jimenez
CFO
Harry Kirsch
Group Communications
Michael Willi
Group QA
Dr. Erwin Vanhaecke
Corporate Secretary
Dr. Charlotte Pamer-Wieser
Pharma
David Epstein
Sandoz
Richard Francis
ECN Members
Corporate Strategy & EA
Paul van Arkel
Vaccines
Dr. Andrin Oswald
OTC
Brian McNamara
Animal Health
Dr. George Gunn
Chief Ethics, Compliance &
Policy Officer
Eric Cornut
Corporate Responsibility
Dr. Jürgen Brokatzky-Geiger
Chairman
Audit & Compliance Committee
Prof. Srikant Datar
General Counsel
Dr. Felix Ehrat
Human Resources
Steven Baert
Novartis Business Services &
Country President Switzerland
André Wyss
14. 14
A brief of all the structures and its roles in the organization.
Pharmaceuticals
Novartis pharmaceuticals provide a range of prescription medicines and pursue the discovery and
development of new products. It is comprised of the business units primary care, oncology,
transplantation, ophthalmics, and mature products.
Primary care includes products for cardiovascular disease, central nervous system disorders,
gastroenterology, dermatology, respiratory disease and the area of rheumatology/bone/hormone
replacement therapy.
The Novartis oncology business unit provides a range of therapies and solutions that change the way
cancer patients live. Its portfolio includes products to treat leukemia, forms of gastrointestinal cancer
(GIST), advanced or metastatic breast cancer and multiple myeloma.
Transplantation and immunology is committed to developing a new range of therapeutic products for the
prophylaxis of organ rejection in order to provide the best choice of drugs to the transplant community.
Novartis ophthalmics deals with the research, development and manufacturing of ophthalmic
pharmaceuticals that assist in the treatment of glaucoma, age-related macular degeneration (AMD), eye
inflammation, ocular allergies, dry eye and other diseases and disorders of the eye.
Mature products is responsible for supporting a range of branded, mostly older products to satisfy
patient needs in various therapeutic areas.
Sandoz
Sandoz, the generic pharmaceuticals division of Novartis, develops, produces and markets medicines no
longer protected by patents, along with pharmaceutical and biotechnological active substances.
15. 15
Consumer Health
Consumer Health Division comprises the following six business units: Sandoz (Novartis generics), over
the counter (OTC), animal health, medical nutrition, infant and baby and CIBA Vision.
The global activities of Novartis Generics were united under the name Sandoz. Sandoz develops,
manufactures and markets these medicines as well as pharmaceutical and biotechnological active
ingredients.
OTC is involved in the development, production and marketing of self-medication products for the in-
home treatment and prevention of medical conditions and ailments. The main product categories are
cough, cold and allergy treatments, gastrointestinal treatments and dermatological treatments, topical
analgesics, mineral supplements and smoking cessation treatments.
Novartis animal health focuses on the well-being of companion animals and on the health and
productivity of farm animals. Most of its products are available by prescription through veterinarians.
Novartis medical nutrition offers a range of enthral nutrition medical food products and services tailored
to the varying needs of patients, health professionals and carers.
The infant and baby line of products includes care and wellness products featuring baby washes,
shampoos, lotions, dental care products, bottles and products for breastfeeding mothers.
CIBA Vision is concerned with research, development and manufacturing of optical and ophthalmic
products and services, including contact lenses, lens care products and ophthalmic surgical products.
Vaccines and Diagnostics
Vaccines and Diagnostics Division provides products to fight more than 20 vaccine-preventable viral
and bacterial diseases as well as blood-testing equipment.
16. 16
MAJOR ISSUES IN MARKETING SECTOR OF NOVARTIS
NOVARTIS-OFF-LABEL MARKETINGAND OTHER MARKETING VIOLATIONS:
Novartis was accused of paying illegal kickbacks to health care professionals through the speaker programs and
the advisory boards, but aside from this argument and guilty to one wrong-doing charge of mislabeling in an
agreement that Novartis announced around in February, the company denied its mistake.
Novartis joins a growing list of pharmaceutical companies that have settled government investigations
into health care fraud in the last few years, including Pfizer, which paid $2.3 billion; Eli Lilly, around
$1.4 billion; Allergan, $600 million and AstraZeneca, $520 million and with Bristol-Myers Squibb,
paying $515 million; and Forest Laboratories, $313 million. Pfizer, Lilly, Allergan and Forest pleaded
guilty to crimes in the cases.
The settlement includes a $170 million criminal fine and $15 million in criminal forfeiture by Novartis
Pharmaceuticals, the United States subsidiary. The plea was announced by the office of the United
States attorney in Philadelphia, who had specialized in health care fraud investigations of companies that
promote drugs for uses not approved by the Food and Drug Administration, known as off-label marking.
“Off-label marketing can undermine the doctor-patient relationship and adversely influence the clear
judgment that a doctor’s patients have come to rely on and trust,” said Zane David Memeger, the United
States attorney.
Federal prosecutors said Novartis illegally promoted Trileptal for neuropathic pain and bipolar disease,
singling out psychiatrists and pain specialists who were known to use the drug off-label. Physicians are
legally permitted to use approved drugs for any purpose, but companies are prohibited from promoting
them for conditions not authorized by the F.D.A. Novartis settled the investigation into the other drugs
for $237.5 million.
In a statement, Novartis said it had been cooperating with the investigations since 2005 and had already
corrected its promotional practices. “We are pleased to have reached resolution on this matter,” said
Andy Wyss, president of Novartis Pharmaceuticals. He added that the company would “continue its
commitment to high standards of ethical business conduct and regulatory compliance in the sale and
marketing of our products.”
17. 17
NOVARTIS DEALS GROUPINCLUDED IN FIXING STOCKISTS FOR A YEAR:
Stockists of Novartis in the nation's most essential local business cautioned the organization a year ago
of horrible practices in the dispersion of Galvus, a medication at the middle of an extortion submitted by
some sales people in the Swiss pharma titan.
The Pharma Wholesalers Association, (PWA), of the Mumbai locale (which likewise incorporates Pune)
asked Novartis to check certain practices, for example, huge rebates and freebies to merchants to offer
loads of Galvus. ET has a duplicate of the letter.
"We request this prerequisite to understand and dishearten any sort of horrible dispersion work on
common in pharmaceutical production network." said the PWA letter of the tended to the appropriation
chief of Novartis India in June 2012. Stockists told ET that Novartis deals agents were putting forth 20%
markdown to choose merchants for the buy of Galvus.
Stockists in the western district had whined that the deals reps of Novartis had been putting forth
gigantic discounts of the medication with a specific end goal to push deals. They were likewise giving
away the medication for nothing on a few occasions. The affiliation had asked the Swiss drug creator to
outfit the buy subtle elements of every last one of stockists of Novartis since January 2012.
Galvus is a heading against diabetes tranquilizes in the nation with a yearly offers of Rs 200 crore. The
opposition to diabetic business sector medication showcase in India is one of the quickest developing
remedial regions with a yearly development of in excess of 20% this business sector is evaluated to be
Rs 3000 crore.
18. 18
UNITED STATES CLAIM BLAMES NOVARTIS FOR HEALTH AWARENESS MISREPRESENTATION
US government has sued Novartis Pharmaceuticals, guaranteeing it offered kickbacks to drug stores to
switch kidney transplant patients from contenders' medications to its own. The common health
awareness misrepresentation claim in US District Court in Manhattan looks for unspecified harms and
common punishments for a plan that the administration said has been done since 2005.
US Attorney Preet Bharara said yesterday that the organization utilized the "draw of kickbacks
camouflaged as refunds" to transform 20 or more drug stores into a deals power for its medication,
Myfortic. He said the organization's activities created general society to pay a huge number of dollars
for kickback-corrupted medications apportioned by drug specialists who had buddied up to Novartis.
Bharara said Novartis is a rehash guilty party, having settled extortion charges focused around kickbacks
short of what three years prior. Novartis said in an announcement that it question the cases and will
guard itself.
It said the examination concerning the organization's associations with strength drug stores identified
with the treatment of Myfortic had been beforehand uncovered. "As a heading medicinal services
organization, Novartis strives to attain elite with high uprightness. NPC is focused on exclusive
requirements of moral business conduct and administrative consistence in the deal and advertising of our
items," the organization said.
In its claim, the legislature said Novartis had camouflaged kickbacks as execution discounts and rebates
to persuade drug stores to switch patients to Myfortic from contender's medications and to contradict the
utilization of a less expensive, nonexclusive immunosuppressant medication.
The administration said Novartis offered one drug specialist in Los Angeles a "reward" discount adding
up to a few hundred thousand dollars to actuate the drug specialist to "shoulder the trouble" of
exchanging 700 to 1,000 transplant patients to Myfortic.
19. 19
FINANCIAL ANALYSIS
The financial performance of Novartis has improved over the years compared to its competitors, many
of which are still struggling to gain good profit margin. Over the past 10 years, Novartis has maintained
steady increase in sales, profit and market share. Its share price has been on the increase ever since being
made public in 1996. The mergers and acquisitions undertaken have contributed to the company’s
growth over the years. Currently, Novartis is ranked second in the world in revenue right behind Pfizer
in the pharma industry and number one in sales.
The above chart shows the company’s net sales by segment. The ‘Vaccines and Diagnostics’ segment
has done better compared to the other three segments. This was before they merged with Alcon in 2011.
Novartis was formed by the merger of three companies and Novartis has been actively merging and
acquiring divisions and adding on to its segment.
20. 20
The above table shows the geographical of Novartis’ net sales and how it has changed in the course of
ten years. In a time frame of ten years, Europe and America have grown massively thanks to the
innovation and research capabilities in those countries. Whereas, in the region of Asia/Africa/Australia,
the growth has been comparatively slow, because of slow advancement of scientific innovation and
research.
While Novartis's first quarter earnings report is pretty stale at this point, it is worth noting that the
company is logging decent growth at a time when many of its peers are struggling to show much of any
momentum. Revenue was up 2% in the last quarter (or 4% in constant currency), with the core
pharmaceutical business the weakest at 0% and 3% growth. Generics and consumer health are both
growing at mid-single digit rates, while the small vaccine and diagnostics business logged a double-digit
constant currency improvement. Alcon results are still a little sluggish, with growth on par with the
pharmaceutical business.
Due in part to the revenue mix, Novartis’ margins are not quite as impressive as some peers. Operating
income rose 1% (or 6% in constant currency), but the 26% operating margin isn't so impressive relative
to Pfizer (NYSE:PFE) at 42% or Roche (OTC:RHHBY) at 31%. This less impressive margin is due at
least in part to the company's very large generics business, as well as the very low margins of the
vaccines/diagnostics business.
21. 21
The above pie chart and table show the comparison of net sales in 2003 and 2013. In 2003, Novartis’
major sales came from Pharmaceuticals (64%) and then from the Consumer Health segment (36%). In
2013, Novartis has now 3 more segments where the Pharmaceuticals and Alcon segment are doing
relatively better.
NET INCOME
NET INCOME (in millions)
YEAR USD
2003 4787
2004 5380
2005 6141
2006 6825
2007 6540
2008 8163
2009 8454
2010 9969
2011 9072
2012 9383
2013 9292
22. 22
In a time frame of ten years, Novartis’ net income has risen well compared to its competitors. It reached
its all time high of 9969 million USD during 2010 and 9292 million USD in 2013.
DRIVER TO RISE IN NET INCOME (2010 onward)
Novartis completes CEO succession process with appointment of Joe Jimenez as new CEO and
simplified leadership organization.
More than 30 drug approvals and full pipeline with 145 projects in pharmaceutical clinical
development, of which 60 involve new molecular entities.
Forward productivity program exceeds savings goal by nearly 50% and a year ahead of schedule
Access-to-medicine programs including medication for malaria and leprosy reach 80 million
patients in 2009 with contributions valued at USD 1.5 billion, or 3% of sales
23. 23
TOTAL ASSETS
TOTAL ASSETS (in
millions)
Year USD
2003 48378
2004 52488
2005 57732
2006 68008
2007 75452
2008 78299
2009 95505
2010 123318
2011 117468
2012 124191
2013 126254
24. 24
SHARE PRICE
The above chart shows the share price of Novartis from 2003 onwards up until 2013. As usual, change
in management, mergers and acquisitions have played a role in the fluctuating share price. Mainly to be
noted is the drastic price decline in 2008 and 2009. The major news in 2008 was Novartis’
announcement of taking a 25% stake in Alcon.
News from 2008: Novartis's share price undervalues the business, the Swiss drug maker’s finance chief
was quoted as saying, and the long-term growth prospects for the industry were good.
"Our price-earnings ratio has roughly halved in the last seven years, while earnings per share have risen
by some 100 per cent. Sooner or later this performance will again be reflected in the share price," Chief
Financial Officer Raymund Breu told the Finanz und Wirtschaft newspaper. Breu acknowledged that
some of Novartis's problems were homemade, such as delays in the introduction of a number of new
drugs. But much of the low valuation had to do with lukewarm investor sentiment towards the sector.
Long-term growth prospects for the pharmaceutical industry were good, Breu said, because of an ageing
population, the rise of diseases linked to an unhealthy lifestyle and higher demand for medicines in
25. 25
emerging countries. Novartis stock still trades at a premium compared to some other European drug
majors, but analysts have questioned whether that is sustainable given its thin portfolio of new drugs.
CONCLUSION, RECOMMENDATIONS, FUTURE PROSPECTS
Pipeline
Novartis has a leading new product pipeline with more than 200 projects in clinical development,
including 144 in the Pharmaceuticals Division. In pipeline highlights, Novartis received three US FDA
Breakthrough Therapy designations. In addition, results from multiple Phase III studies underscored the
strength of our pipeline in dermatology: AIN457 (secukinumab) showed superior efficacy in moderate-
to severe plaque psoriasis over the current standard of care, and Xolair (omalizumab) produced
clinically meaningful improvement in chronic spontaneous urticaria. Additionally, LBH589
(panobinostat) significantly extended time without disease progression in patients with relapsed or
relapsed and refractory multiple myeloma.
Chairman of the Board, Joerg Reinhardt quoted as saying,
“This success was due primarily to the continued dynamic development of our largest division,
pharmaceuticals, which has one of the industry’s most robust product portfolios. Our eye care division,
Alcon, and our generics business, Sandoz, also contributed to the positive result. With the market launch
of state-of-the-art eye surgery systems, Alcon strengthened its leading position in the fast-growing area
of cataract operations, while Sandoz gained further market share amid accelerated demand for
sophisticated biosimilars.”
Novartis’ continuous effort in innovation, research and corporate social responsibility has given it a
much more than needed boost into the future.